Drug Profile
Research programme: bone disease peptide therapeutics - Alize Pharma III SAS
Alternative Names: I-HBD1 analogs - Alize Pharma III SASLatest Information Update: 28 Jun 2020
Price :
$50
*
At a glance
- Originator University of Maine; University of North Carolina at Chapel Hill
- Developer Alize Pharma III SAS; New Paradigm Therapeutics
- Class Peptides
- Mechanism of Action Insulin-like growth factor binding protein 2 modulators; Osteoblast stimulants; Osteoclast inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Osteoporosis; Postmenopausal osteoporosis
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for preclinical development in Postmenopausal-osteoporosis in USA (Parenteral)
- 28 Jan 2019 No recent reports of development identified for preclinical development in Osteoporosis in USA
- 01 May 2016 Preclinical trials in Postmenopausal osteoporosis in USA (Parenteral)